Tsr Profitability Index - Excellent Score of 84.38
Tsr Stability Index - Excellent Score of 89.06
Altman Z Score of 8.97 suggests good Stability
Earning Yield of 8.03 %
YoY Net Margin Jump by 322.31%
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 89.74%
During the past twelve months, the company has given a strong Return On Asset of 45.73%
During the past twelve months, the company has given a strong Net Margin of 51.17%
All key Trailing Twelve Months Margin growing by 15 %
Steady View
Annual sales of the company is increased for three years in a row
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Company financial liquidity has improved
Book Value in last 3 years is trending up
Good Return On Capital Employed of 14.30
Risky View
Tsr Growth Index - Poor Score of 34.44
Price Very close to One year Low made on 03-Feb-23
Stock Returns is less than Nifty returns for consequitive last three years
Price to Book Ratio of 7.92 suggesting that it is very expensive
Terrific Steady Risky Stock View - Fundamental Snapshot
Share Overview
Promoter Owned
75.00 %
Institution Owned
12.70 %
Public/Others
12.30 %
Outstanding Shares
16.94 Cr
Floating Shares
4.11 Cr
Floating / Outstanding
24.24%
Book Value/Share
157.20
Face value
10.00
Share Holding
Annual Key Income Statement of GLAXO
Period
31_Mar_2022
31_Mar_2021
Growth
Net Income From Continuing Ops
380.77
287.27
32.55 %
Net Income
1694.72
358.15
373.19 %
Operating Income
691.70
516.00
34.05 %
Total Revenue
3278.03
2925.60
12.05 %
Operating Expense
2586.33
2409.60
7.33 %
Interest Expense
2.00
3.53
43.34 %
Tax Expense
398.28
166.72
138.89 %
Income Before tax
779.05
453.99
71.60 %
Gross Profit
1921.84
1804.19
6.52 %
Dividend Paid
-506.63
-677.62
25.23 %
Quarterly Key Income Statement of GLAXO
Period
30_Sep_2022
30_Jun_2022
Growth
Net Income From Continuing Ops
193.42
116.23
66.41 %
Net Income
193.42
119.28
62.16 %
Operating Income
256.93
133.10
93.04 %
Total Revenue
916.87
745.10
23.05 %
Operating Expense
659.94
612.00
7.83 %
Interest Expense
0.390
0.680
42.65 %
Tax Expense
68.73
43.80
56.92 %
Income Before tax
262.15
160.03
63.81 %
Gross Profit
551.77
458.20
20.42 %
Dividend Paid
0
0
%
Key Balance Sheet Fields
Period
31_Mar_2022
31-Mar-21
Growth
Common Stock
169.41
169.41
0 %
Current Liabilities
1698.43
1354.58
25.38 %
Total Liabilities
1970.32
1636.39
20.41 %
Current Assets
3708.03
2202.64
68.34 %
Total Assets
4633.28
3114.65
48.76 %
Working capital
2009.60
848.06
136.96 %
Accounts Payable
570.55
466.13
22.40 %
Inventory
534.70
546.70
2.19 %
Net Receivable
205.24
215.60
4.81 %
Key Cash Flow Fields
Period
31_Mar_2022
31_Mar_2021
Growth
Cash EPS
26.50
21.60
22.69 %
Cash From Investment Activity
-405.51
418.59
196.88 %
Cash From Financial Activity
-524.24
-696.14
24.69 %
Cash Operational Activity
810.75
577.93
40.29 %
Net Cash Flow
-119.00
300.38
139.62 %
NetIncome
1694.72
358.15
373.19 %
Capital Expenditure
34.64
44.23
21.68 %
Change To Inventory
12.00
-46.79
125.65 %
About GlaxoSmithKline Pharmaceuticals Limited GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
TSR Tech Strength is based on Deep Analysis, Back Testing and Historical Trend Analysis using Machine Learning. Overall Technical Strength is based on 50+ indicators including Technicals, moving Avg, chart patterns, candlestick and proprietary algorithms.Technical Strength is calculate from 5Mins Ticck to One Month Tick
TSR Growth analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access Growth Potential
TSR Value analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access its value
This is an automated process and in NO WAY should be considered as a tip as its based on past data. We strongly recommend to use these signals for information only and seek advise from a certified professional for any trading decision.If you like it then please share. The more the visitors the more the innovations. Feedback
We are working on fundamental strength also. Please share your views to help shape up the requirement.
